Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biotech stocks had a so-so year in 2021, as the Covid-19-induced boost the sector received in the previous year wore off. The iShares Biotechnology ETF (NASDAQ: IBB ), which is considered a proxy for the sector, gaine...
Following back-to-back intraday gains, the shares of commercial-stage biotech, Akebia Therapeutics (AKBA -10.0%) have dropped on Friday after JPMorgan highlighted potential regulatory issues the company is likely to face in its marketing application for vadadustat. In June, Akebia (NASDAQ:AKB...
Penny stocks can be hot or cold, depending on who you ask. But in the stock market today, there’s no shortage of big movers. Maybe they jump for a day or go on to rally for weeks; the potential for penny stocks to make you money is undeniable. Assuming you’ve got a sto...
Akebia press release (NASDAQ:AKBA): Q4 GAAP EPS of -$0.40 misses by $0.09. Revenue of $59.61M (+5.1% Y/Y) beats by $7.84M. For further details see: Akebia GAAP EPS of -$0.40 misses by $0.09, revenue of $59.61M beats by $7.84M
Akebia Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Business Highlights - Akebia is launch-ready pending FDA decision for vadadustat on PDUFA date, March 29, 2022 - Amended agreement with Vifor Pharma Group strengthens collaboration for...
Akebia (NASDAQ:AKBA) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.30 and the consensus Revenue Estimate is $51.77M (-8.7% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. R...
ADT,AGEN,AKBA,ALBO,AMRN,AMRS,AXSM,AZO,OTCPK:BAYZF,BIDU,BLDR,BMO,BNS,BSY,CCCS,CHS,CMRX,CRON,DPZ,EHTH,EPZM,EVRI,FOUR,OTCQX:GTBIF,HGV,HOV,HRL,HTA,HZNP,IGT,IQ,ITCI,KSS,KTB,LILM,MANU,MCRB,MLCO,NFE,OTCQB:NLST,NUWE,OKE,PIRS,PLTK,PRGO,QTRX,REGI,RYTM,SE,SJM,TGT,TGTX,TLS,TWNK,UWMC,VFF,VRTV,WEN,WKHS,XXI...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If we’re being completely honest, participating in the equities market doesn’t seem so inviting at the present juncture. With the dual threat of rising consumer inflation and the escalation of tensions in ea...
Akebia Therapeutics (AKBA -0.8%) amended a license agreement with Vifor Pharma < > for the former's vadadustat, a potential treatment for anemia due to chronic kidney disease. Under the earlier agreement, Vifor (OTCPK:GNHAF) received an exclusive license to sell vadadustat to Fre...
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat Launch Agreement Leverages Vifor Pharma's Exclusive Distribution Arrangement with Certain Dialysis Organizations Agreement Defines Profit Share Economics of...
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets PR Newswire Akebia regains full rights to sell Vafseo® (vadadustat) Tablets in the U.S. following the execution of a royalty-based termination agreement wit...
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference PR Newswire CAMBRIDGE, Mass. , June 27, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purp...
Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer PR Newswire CAMBRIDGE, Mass. , June 24, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with t...